Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants.
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants.
复制标题
DOI：
10.1016/j.isci.2023.106124
复制
发表时间：
2023-03-17
期刊：
影响因子：
5.8
通讯作者：
Sakuntabhai, Anavaj
中科院分区：
文献类型：
--
作者：
Chauvin, Camille;Levillayer, Laurine;Roumier, Mathilde;Nielly, Hubert;Roth, Claude;Karnam, Anupama;Bonam, Srinivasa Reddy;Bourgarit, Anne;Dubost, Clement;Bousquet, Aurore;Le Burel, Sebastien;Mestiri, Raphaele;Sene, Daminen;Galland, Joris;Vasse, Marc;Groh, Matthieu;Le Marchand, Mathilde;Vassord-Dang, Camille;Gautier, Jean-Francois;Nhan, Pham-Thi;Verny, Christian;Pitaro, Bruno;Planchais, Cyril;Mouquet, Hugo;Paul, Richard;Simon-Loriere, Etienne;Bayry, Jagadeesh;Gilardin, Laurent;Sakuntabhai, Anavaj
尽管托珠单抗治疗2019冠状病毒病（COVID-19）重症和危重症患者已在临床层面证明了其疗效，但目前几乎没有证据支持短期使用白细胞介素-6受体阻断治疗对恢复期COVID-19患者的B细胞亚群和SARS-CoV-2变异体的交叉中和作用。我们对总共69名托西珠单抗治疗和未治疗的恢复期COVID-19患者进行了免疫学分析。我们观察到SARS-CoV-2特异性IgG 1滴度取决于疾病的严重程度，而不是托珠单抗治疗。感染了祖先变异体的治疗和未治疗患者的血浆对SARS-CoV-2的祖先病毒和α、β和δ变异体表现出强中和活性，而γ和Omicron病毒对血清中和不太敏感。总体而言，我们观察到，尽管短期托珠单抗治疗在改变与COVID-19感染相关的细胞因子风暴方面具有临床益处，但B细胞和IgG对刺突抗原的应答的稳健性没有改变。SARS-CoV-2特异性IgG 1滴度取决于疾病严重程度，但不取决于托珠单抗托珠单抗对B细胞亚群和SARS-CoV-2特异性IgG 1无重大影响托珠单抗不会改变血浆病毒对SARS-CoV-2 VOC的中和能力健康科学;病毒学;治疗;免疫学。
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens. SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab No major impact of tocilizumab on the B cell subsets and SARS-CoV-2-specific IgG1 Tocilizumab does not alter plasma virus neutralization capacity for SARS-CoV-2 VOCs Health sciences; Virology; Treatment; Immunology.
登录
查看更多内容
影响因子：
7.3
作者：
Moens L;Tangye SG
通讯作者：
Tangye SG
影响因子：
27.4
作者：
Mori, Shunsuke;Ueki, Yukitaka;Oishi, Kazunori
通讯作者：
Oishi, Kazunori
影响因子：
--
作者：
Roll, Petra;Muhammad, Khalid;Tony, Hans-Peter
通讯作者：
Tony, Hans-Peter
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
DOI：
10.1056/nejmoa2028700
发表时间：
2021-04-22
期刊：
The New England journal of medicine
影响因子：
--
作者：
Rosas IO;Bräu N;Waters M;Go RC;Hunter BD;Bhagani S;Skiest D;Aziz MS;Cooper N;Douglas IS;Savic S;Youngstein T;Del Sorbo L;Cubillo Gracian A;De La Zerda DJ;Ustianowski A;Bao M;Dimonaco S;Graham E;Matharu B;Spotswood H;Tsai L;Malhotra A
通讯作者：
Malhotra A